IQVIA’s MedTech white paper highlights how shifting U.S. tariffs and retaliatory measures are straining global medical device supply chains, with projected industry costs of $4B in 2025. Companies like Johnson & Johnson and Abbott report hundreds of millions in tariff impacts, prompting strategies such as localizing production, regionalizing supply, and financial adjustments. MedTech is especially vulnerable due to complex global supply chains, customized products, and thinner margins. High-risk countries include Ireland, Costa Rica, China, and Switzerland. IQVIA advises diversification, scenario modeling, regulatory intelligence, and advocacy for zero-for-zero tariff exemptions.

Join for free to read